FGF receptor inhibitor BGJ398 partially rescues osteoarthritis-like phenotype in older high molecular weight FGF2 transgenic mice via multiple mechanisms

• Published in: Scientific reports Vol. 12; no. 1; p. 15968
• Main Authors: Hurley, Marja M., Coffin, J. Douglas, Doetschman, Thomas, Valera, Christina, Clarke, Kai, Xiao, Liping
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.09.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250/808; 692/163/2743/316; Animal models; Animals; Arthritis; Bone histomorphometry; Bone morphogenetic protein 2; Bone turnover; Cartilage; Cartilage (articular); Cartilage diseases; Cbfa-1 protein; Collagenase 3; Computed tomography; Core Binding Factor Alpha 1 Subunit - genetics; Endopeptidases; Enzyme inhibitors; Familial Hypophosphatemic Rickets - genetics; Female; Fibroblast growth factor 2; Fibroblast Growth Factor 2 - genetics; Fibroblast growth factor 23; Fibroblast growth factor receptor 1; Fibroblast growth factor receptors; Fibroblasts; Gene expression; Growth factors; Histology; Homeostasis; Humanities and Social Sciences; Hypophosphatemia; Isoforms; Kinases; Matrix Metalloproteinase 13 - genetics; Mice; Mice, Transgenic; Molecular Weight; multidisciplinary; Osteoarthritis; Osteoarthritis - drug therapy; Osteoarthritis - genetics; Osteoarthritis - metabolism; Pathogenesis; Phenotype; Phenotypes; Phenylurea Compounds; Protease Inhibitors; Protein Isoforms - metabolism; Proteins; Pyrimidines; Science; Science (multidisciplinary); Serine - genetics; Signal transduction; Subchondral bone; Transgenic animals; Transgenic mice
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-20269-6

We have used Basic Fibroblast Growth Factor (FGF2) transgenic mice as experimental models for human X-linked hypophosphatemia (XLH)-related degenerative osteoarthritis (OA) to investigate the pathogenesis of the disease and to test potential pharmacotherapies for treatment. This study tested the efficacy of BJG398, a small molecule fibroblast growth factor receptor tyrosine kinase (FGFRTK) inhibitor, to rescue the knee joint osteoarthritis phenotype in High Molecular Weight fibroblast growth factor 2 transgenic (HMWTgFGF2) mice. BJG398 was administered in vivo to 8-month-old female HMWTgFGF2 mice for six weeks. Histomorphometry, immunohistochemistry and micro-CT were used to examine the knee joints in BGJ398-treated and control mice. We assessed: Fibroblast Growth Factor 23 (FGF23) expression and FGFR1 activity; Matrix metalloproteinase 13 (MMP13) and Aggrecanase2 (ADAMTS5) expression; then signaling by SMAD1/5/8-pSMAD6, pERK1/2 and Runt-related transcription factor 2 (RUNX2). Using PrimePCR arrays, we identified a contributing role for major target genes in the TGFB/BMP2 signaling pathway that were regulated by BGJ398. BGJ398 inhibited HMWFGF2/FGF23-induced increase in bone morphogenic protein receptor-1, bone morphogenic protein-2 and 4 and Serine peptidase inhibitor, clade E, member 1. The results from Micro-CT and histology show BGJ398 treatment rescued the OA changes in subchondral bone and knee articular cartilage of HMWTgFGF2 mice. The gene expression and signal transduction results provide convincing evidence that HMWFGF2 generates OA through FGFRTK with characteristic downstream signaling that defines OA, namely: increased FGF23-FGFR1 activity with BMP-BMPR, activation of pSMAD1/5/8-RUNX2 and pERK signaling pathways, then upregulation of MMP13 and ADAMTS5 to degrade matrix. BGJ398 treatment effectively reversed these OA molecular phenotypes, providing further evidence that the OA generated by HMWFGF2 in the transgenic mice is FGFR-mediated and phenocopies the OA found in the Hyp mouse homolog of XLH with a spontaneous mutation in the Phex (phosphate regulating endopeptidase on the X chromosome) gene and human XLH-OA. Overall, the results obtained here explain how the pleotropic effects of FGF2 emanate from the different functions of HMW protein isoforms for cartilage and bone homeostasis, and the pathogenesis of XLH-degenerative osteoarthropathy. BGJ398 inhibits HMWFGF2-induced osteoarthritis via multiple mechanisms. These results provided important scientific evidence for the potential application of BGJ398 as a therapeutic agent for osteoarthritis in XLH.